{"cmr":"de-cm-kg/XETRA/PTP","since":null,"total":13,"cursor":0,"limit":50,"next_cursor":null,"events":[{"cmr":"de-cm-kg/XETRA/PTP","date":"2026-11-04","event_type":"corporate_news","title":"Pentixapharm Announces Progress of Pivotal Phase 3 PANDA Study; Will Host Third Quarter Webcast on November 12, 2026 | Corporate - EQS News","category":"corporate","language":"en","wire":"EQS News","source":"EQS News","url":"https://www.eqs-news.com/news/corporate/pentixapharm-announces-progress-of-pivotal-phase-3-panda-study-will-host-third-quarter-webcast-on-november-12-2026/ef723530-b5f8-4566-a1e0-6e8b7df1f4b6_en","read_by":"Tavily search (eqs-news.com) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"eHAR0kciNLG3WgqIzv5QWgwhsi_kOrsIBg4sss_cCtt2zqGbB2E0SCPztWG6IgJHTy3grQ_nsfuIA_PbehxeDA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"de-cm-kg/XETRA/PTP","date":"2026-11-04","event_type":"corporate_news","title":"Pentixapharm meldet Fortschritte bei der zulassungsrelevanten Phase-3-Studie PANDA und lädt am 12. November 2026 zum Q3-Webcast ein | Corporate - EQS News","category":"corporate-news","language":"de","wire":"EQS News","source":"EQS News","url":"https://www.eqs-news.com/news/corporate-news/pentixapharm-meldet-fortschritte-bei-der-zulassungsrelevanten-phase-3-studie-panda-und-laedt-am-12-november-2026-zum-q3-webcast-ein/ef723530-b5f8-4566-a1e0-6e8b7df1f4b6_de","read_by":"Tavily search (eqs-news.com) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"btSRmGZzYNfDkudKXvTHwaVpOlaDUMGbQbWVcE9ABAkZVhmj54VSChvYMQ1BdJp6iuI-afArRoWAm8pjBie-Aw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"de-cm-kg/XETRA/PTP","date":"2026-11-04","event_type":"corporate_news","title":"Original-Research: Pentixapharm Holding AG (von BankM AG): Kaufen | Research - EQS News","category":"research","language":"de","wire":"EQS News","source":"EQS News","url":"https://www.eqs-news.com/news/research/original-research-pentixapharm-holding-ag-von-bankm-ag-kaufen/4c13b510-cf19-4576-9c42-056d17854a82_de","read_by":"Tavily search (eqs-news.com) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"tv2GbIyWOOLr-OhCGZb-vfUefaN03z-nYWEhdhDbO3y4TUzvTDyjHUV1WPp10eBU5G19PBzZM1gF_i1HxJUiAA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"de-cm-kg/XETRA/PTP","date":"2026-11-04","event_type":"newswire_release","title":"Pentixapharm Announces Progress of Pivotal Phase 3 PANDA Study; Will Host Third Quarter Webcast on November 12, 2026","wire":"PR Newswire","source":"PR Newswire","url":"https://www.prnewswire.com/news-releases/pentixapharm-announces-progress-of-pivotal-phase-3-panda-study-will-host-third-quarter-webcast-on-november-12-2026-302928975.html","read_by":"Tavily search (wire domains) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"HzAqVwBVD6lgB6ImRx_1mkuw1LkbxkxjjCMPfVyjAOokRMNffON1aaZo9ehSIVVDX9h19eDKBmn2I4__y0ugDw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"de-cm-kg/XETRA/PTP","date":"2026-10-13","event_type":"corporate_news","title":"Pentixapharm Holding AG: Vorabbekanntmachung über ...","category":"vorabbekanntmachung-finanzberichte","language":"de","wire":"EQS News","source":"EQS News","url":"https://www.eqs-news.com/news/vorabbekanntmachung-finanzberichte/pentixapharm-holding-ag-vorabbekanntmachung-ueber-die-veroeffentlichung-von-quartalsberichten-und-quartals-zwischenmitteilungen/4222ec08-6c34-48fc-8525-179023ed9860_de","read_by":"Tavily search (eqs-news.com) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"LGHrjJ1up1HguFPRQzAo_4J6-G9viqD-j8r4KSfp6dKyazLD0wezNa1lvEeSRA5Edet0M5QMRNm3QacK6CttBw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"de-cm-kg/XETRA/PTP","date":"2026-10-13","event_type":"results","title":"Pentixapharm Holding AG: Preliminary announcement of ...","category":"financial-reports","language":"en","wire":"EQS News","source":"EQS News","url":"https://www.eqs-news.com/news/financial-reports/pentixapharm-holding-ag-preliminary-announcement-of-the-publication-of-quarterly-reports-and-quarterly-interim-statements/4222ec08-6c34-48fc-8525-179023ed9860_en","read_by":"Tavily search (eqs-news.com) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"XYDRDVv-yyrP9fyK-P2MPVLGw6M5idduiMGXQkrNM37mY5RkB8MRGr7giRxqVJNKgA1IbVEY6puN2HvrzaD_DA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"de-cm-kg/XETRA/PTP","date":"2026-07-15","event_type":"corporate_news","title":"Original-Research: Pentixapharm Holding AG (von NuWays AG): BUY","category":"research","language":"en","wire":"EQS News","source":"EQS News","url":"https://www.eqs-news.com/news/research/original-research-pentixapharm-holding-ag-von-nuways-ag-buy/8c874448-1320-4c96-970b-93a3753dcd27_en","read_by":"Tavily search (eqs-news.com) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"t_xPmErl-1LVjdSeTxWcjPWsN42b1HGOMrnskR-Wew_zgl5GUQSbpjKB1EHQPugiXXxMvSDyZhrY_QpMgNMGDw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"de-cm-kg/XETRA/PTP","date":"2026-07-09","event_type":"corporate_news","title":"Pentixapharm erhält FDA-Fast-Track-Status für Phase-3 ... - EQS News","category":"corporate","language":"de","wire":"EQS News","source":"EQS News","url":"https://www.eqs-news.com/news/corporate/pentixapharm-erhaelt-fda-fast-track-status-fuer-phase-3-diagnostikum-e281b6e281b8gaga-pentixafor/239d14bc-6e9e-4077-9909-43e52edf7a09_de","read_by":"Tavily search (eqs-news.com) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"Py8qWZmmfrfh92AvruoQYTPTisGztc4hPI7zZSzCU-n6UKcE5jPn0dGjiNrOpVf-HGmWbrNJknsVp1AUEA-jBA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"de-cm-kg/XETRA/PTP","date":"2026-07-01","event_type":"corporate_news","title":"Pentixapharm Launches Rights Issue to Fund PANDA Phase 3 and ...","category":"corporate","language":"en","wire":"EQS News","source":"EQS News","url":"https://www.eqs-news.com/news/corporate/pentixapharm-launches-rights-issue-to-fund-panda-phase-3-and-u-s-expansion/ae12da6b-c2ae-4931-b73c-7704185c5ad9_en","read_by":"Tavily search (eqs-news.com) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"A5aVrTOFbWf-zwl4BsZYdmI3Y6Dgj0Ksx1C5aBQBEa63Gzfco_ekZrvyP4LFI0x_gqZvo33JXuqLljZ1ErqhBA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"de-cm-kg/XETRA/PTP","date":"2026-07-01","event_type":"corporate_news","title":"Pentixapharm beschließt Bezugsrechtskapitalerhöhung zur ...","category":"corporate","language":"de","wire":"EQS News","source":"EQS News","url":"https://www.eqs-news.com/news/corporate/pentixapharm-beschliesst-bezugsrechtskapitalerhoehung-zur-finanzierung-der-panda-phase-3-studie-und-der-us-expansion/ae12da6b-c2ae-4931-b73c-7704185c5ad9_de","read_by":"Tavily search (eqs-news.com) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"ziIVV-Fzrx4j9BjUya2NC0AcYnQYsBFd0Jm9RN9HCSzmcjeLdtY-qKtGKG-cw5G2tNK0qMHAbtEJVUPCOutUDg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"de-cm-kg/XETRA/PTP","date":"2026-02-05","event_type":"corporate_news","title":"Pentixapharm Announces Peer-Reviewed Phase 2 Data Back Use of PENTIXAFOR as a Superior Non-invasive PET-Diagnostic for Primary Aldosteronism | Corporate - EQS News","category":"corporate","language":"en","wire":"EQS News","source":"EQS News","url":"https://www.eqs-news.com/news/corporate/pentixapharm-announces-peer-reviewed-phase-2-data-back-use-of-pentixafor-as-a-superior-non-invasive-pet-diagnostic-for-primary-aldosteronism/ca5805ea-f451-4ec9-97e5-23fd7befdfab_en","read_by":"Tavily search (eqs-news.com) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"UTdkZpSLbyXweu9R67fdHYN9A-QWMl9l7HsEp4BgcEyNnrspKiHYN9kx50AKhnld3WZ1pqTeUXCYOlVbyCycBA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"de-cm-kg/XETRA/PTP","date":"2026-01-07","event_type":"corporate_news","title":"Pentixapharm Receives FDA Feedback for Phase 3 Diagnostic ...","category":"corporate-news","language":"en","wire":"EQS News","source":"EQS News","url":"https://www.eqs-news.com/news/corporate-news/pentixapharm-receives-fda-feedback-for-phase-3-diagnostic-study-in-hypertension/b59a1556-c9f2-47f8-b5e9-8bbf0a4f474f_en","read_by":"Tavily search (eqs-news.com) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"DMexVAhWORHeR0G1KHODizq0GGM7wJAFA2R47XUEpPCCxzqC_WBx2f4YyxvVIP3QO-NUpQRJ5mFvr6QzicDuAA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"de-cm-kg/XETRA/PTP","date":"2025-10-06","event_type":"corporate_news","title":"Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New Clinical Findings at EANM 2025 | Corporate - EQS News","category":"corporate","wire":"EQS News","source":"EQS News","url":"https://www.eqs-news.com/news/corporate/pentixapharm-highlights-expanding-cxcr4-radiopharmaceutical-platform-with-new-clinical-findings-at-eanm-2025/78fc80e1-04d0-47ab-8e04-787116388f1e","read_by":"Tavily search (eqs-news.com) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"hWsaeCNv7z0cWtQwzYPidhbEUaJ9zpJ4fhXjGmzpVqguxBy_s47hjdP60znYNOEtnzC4m-LX_F_eL05uCvQyAQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}}],"events_signed":"allooloo-cmr-2026-10"}